Estradiol/progesterone -TherapeuticsMD

Drug Profile

Estradiol/progesterone -TherapeuticsMD

Alternative Names: 17β-estradiol/progesterone -TherapeuticsMD; Progesterone/estradiol - TherapeuticsMD; TX 12-001-HR; TX-001HR; TX-006HR; TX-008HR

Latest Information Update: 04 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TherapeuticsMD
  • Class Estradiol congeners; Estrenes; Hormonal replacements; Pregnenediones
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Menopausal syndrome
  • Phase III Endometrial hyperplasia

Most Recent Events

  • 04 Jun 2018 Chemical structure information added
  • 17 Apr 2018 Pharmacokinetics data from two phase I trials in healthy volunteers presented at the 100th Annual Meeting of the Endocrine Society (ENDO-2018)
  • 17 Mar 2018 Updated efficacy data from the phase III REPLENISH trial in Menopausal syndrome presented at The 100th Annual Meeting of the Endocrine Society (ENDO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top